How would you manage anti-CRMP5 related paraneoplastic myelopathy in a small cell lung cancer patient post-chemoimmunotherapy, that is refractory to high dose steroids and PLEX?
Should the patient receive cancer directed therapy (eg tarlatamab) even if the cancer appears to be controlled off of treatment?